New Chroma Medicine board member Jeff Marrazzo
October 4, 2022 07:00 AM EDTUpdated 07:25 AM
People
Bioregnum

Jeff Mar­raz­zo has found a buzzy new biotech cause to cham­pi­on. And once again, he's all in

Jeff Mar­raz­zo is one of those biotech ex­ecs who has al­ways been fo­cused on the next big goal. He has a track record for meet­ing …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Re­gen­eron plans to buy 23andMe for $256M

Ex­clu­sive: Cell­Cen­tric col­lects $120M to treat mul­ti­ple myelo­ma with a cap­sule

Ap­n­imed posts first set of Phase 3 sleep ap­nea re­sults, aims for ap­proval fil­ing in 2026

FDA ap­proves No­vavax's Covid vac­cine af­ter six-week de­lay, but for a small­er pop­u­la­tion

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times